Cardiovascular News Round-up
Tags: CARDIOVASCULAR system -- Diseases; PHARMACEUTICAL industry; CLINICAL trials; THROMBOEMBOLISM; DRUGS -- Effectiveness
Related Articles
- Fondaparinux was as effective as (noninferior to) enoxaparin in
acute symptomatic deep venous thrombosis. // ACP Journal Club;Nov/Dec2004, Vol. 141 Issue 3, p74
The article addresses the question whether fondaparinux is as effective as (noninferior to) enoxaparin for reducing symptomatic recurrent venous thromboembolic complications, major bleeding, or all-cause mortality in patients with acute symptomatic deep venous thrombosis (DVT). The article...
- New study supports push for tougher lipid targets. Wilkinson, Emma // Pulse;3/19/2005, Vol. 65 Issue 11, p15
Reports on the efficacy of pushing down lipid levels below current targets in patients with coronary heart disease based on a clinical trial in Great Britain. Indication of the results that there is little evidence for aggressively chasing cholesterol targets; Percentage of reduction in major...
- Rimonabant did not lower percent atheroma volume. Haigh, Christen; Raible, Eric // Endocrine Today;5/10/2008, Vol. 6 Issue 8, p7
The article presents the results of a clinical trial that assessed the effectiveness of cannabinoid receptor antagonist rimonabant in treating obesity-related atherosclerotic disease. The drug has succeeded in lowering total atheroma volume in patients with abdominal adiposity, but failed to...
- Tips from Other Journals. MOON, KENNETH T. // American Family Physician;10/15/2009, Vol. 80 Issue 8, p882
The article discusses research on the findings of the "Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial" (ALLHAT) in 2000. It references the study "ALLHAT Findings Revisited in the Context of Subsequent Analyses, Other Trials, and Meta-analyses," by J. T. Wright Jr....
- Is there a deleterious effect of erythropoietin in end-stage renal disease? Singh, Ajay K. // Kidney International;Sep2011, Vol. 80 Issue 6, p569
The use of erythropoiesis-stimulating agents (ESAs) in patients with chronic kidney disease has declined as randomized controlled trials have demonstrated increased risk of cardiovascular complications and mortality without a marked benefit in quality of life. Several studies have suggested that...
- Ticagrelor was more effective than clopidogrel in acute coronary syndromes with planned invasive treatment. Brophy, James M. // ACP Journal Club;5/18/2010, Vol. 152 Issue 5, p3
The article reports on a study that discusses safety and efficiency of ticagrelor and clopidogrel in patients with planned invasive management of an acute coronary syndrome (ACS). As stated, based on a secondary analysis of randomized controlled trial, thousands of patients were admitted for an...
- Ticagrelor Superior to Clopidogrel in Reducing MI, Stroke, and CV Death in ACS (PLATO). // MD Conference Express;Nov2009, p16
The article highlights results of the study Platelet Inhibition and Patient Outcomes (PLATO), presented by Professor Lars Wallentin of Uppsala Clinical Research Center in Uppsala, Sweden. It is stressed that the result of the clinical trial found out that in patients with acute coronary syndrome...
- Atorvastatin Delays Cardiovascular Disease in Patients with Diabetes. Barry, Henry // American Family Physician;1/15/2005, Vol. 71 Issue 2, p347
Discusses research being done on the effectiveness of atorvastatin in the primary prevention of cardiovascular disease in adults with diabetes mellitus. Reference to a study by H. M. Colhoun et al published in the August 21, 2004 issue of "Lancet"; Number of study participants; Percentage of...
- Gilead Sciences and Cardiovascular Research Foundation Initiate Phase 3 Clinical Trial with Ranolazine in Patients Who Have Undergone PCI with a History of Prior Chronic Angina. // Biomedical Market Newsletter;11/9/2011, Vol. 21, p60
The article reports on the phase III clinical trial conducted by Gilead Sciences Inc. and the Cardiovascular Research Foundation (CRF) on the effectiveness of ranolazine. It mentions that Gilead and CRF are evaluating the utility of ranolazine in preventing adverse cardiovascular effects after...
